Ontology highlight
ABSTRACT: Background
HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of HER2 directed therapy have been reported in small studies. However, reliable estimates of the prevalence of HER2 positivity in SGC and its various histological subtypes are lacking.Objective
To assess the prevalence of HER2 positivity in histological subtypes of salivary gland carcinomas (SGC).Methods
Studies were identified by a systematic review of the literature. Data on in situ hybridization (ISH) and immunohistochemistry (IHC) were extracted to derive pooled prevalence estimates calculated by a random effects model. Characteristics of the studies were extracted for subgroup analysis.Results
Fifty studies including 3372 patients were identified, providing data on
SUBMITTER: Egebjerg K
PROVIDER: S-EPMC8264509 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature